Clinical News

Imbruvica (Ibrutinib) First Drug Approved Specifically for Marginal-Zone Lymphoma

Lisa A. Raedler, PhD, RPh

August 2017, Vol 7, No 8 - Drug Update

Marginal-zone lymphoma (MZL) is a malignancy that arises from B-lymphocytes in the marginal zone of lymphoid tissue. This slow-growing indolent B-cell lymphoma represents approximately 12% of all cases of non-Hodgkin lymphoma (NHL) in adults. MZL is divided into 3 subtypes, including mucosa-associated lymphoid tissue (MALT), nodal MZL, and splenic MZL. [ Read More ]

Select Clinical Trials Currently Enrolling Patients with Leukemia

July 2017, Vol 7, No 7 - Clinical Trials Tracker

The following clinical trials represent a selection of key studies that are currently recruiting patients with leukemia for inclusion in investigations of new therapies or new regimens of existing treatments for patients with leukemia. Each description includes the NLM Identifier to be used as a reference with ClinicalTrials.gov. This information can help oncology practice managers and providers direct eligible patients to an appropriate clinical trial. [ Read More ]

Select Clinical Trials Currently Enrolling Patients with Melanoma

June 2017, Vol 7, No 6 - Clinical Trials Tracker

The following clinical trials represent a selection of key studies that are currently recruiting patients with melanoma for inclusion in investigations of new therapies or new regimens of existing treatments for patients with melanoma. Each description includes the NLM Identifier to be used as a reference with ClinicalTrials.gov. This information can help oncology practice managers and providers direct eligible patients to an appropriate clinical trial. [ Read More ]

Select Clinical Trials Currently Enrolling Patients with Brain Cancer

May 2017, Vol 7, No 5 - Clinical Trials Tracker

The following clinical trials represent a selection of key studies that are currently recruiting patients with brain cancer for inclusion in investigations of new therapies or new regimens of existing treatments for patients with brain cancer. Each description includes the NLM Identifier to be used as a reference with ClinicalTrials.gov. This information can help oncology practice managers and providers direct eligible patients to an appropriate clinical trial. [ Read More ]

Select Clinical Trials Currently Enrolling Patients with Multiple Myeloma

March 2017, Vol 7, No 3 - Clinical Trials Tracker

The following clinical trials represent a selection of key studies that are currently recruiting patients with multiple myeloma for inclusion in investigations of new therapies or new regimens of existing treatments for patients with multiple myeloma. Each description includes the NLM Identifier to be used as a reference with ClinicalTrials.gov. This information can help oncology practice managers and providers direct eligible patients to an appropriate clinical trial. [ Read More ]

Lenvima (Lenvatinib) Approved in Combination with Everolimus for Patients with Advanced Renal-Cell Carcinoma

Loretta Fala

February 2017, Vol 7, No 2 - Drug Update

Approximately 394,336 Amer­icans were living with kidney cancer in 2013. In 2016 alone, an estimated 62,700 people were diagnosed with kidney cancer, and 14,240 people died from the disease. Renal-cell carcinoma (RCC), the most common type of kidney cancer, accounts for 85% to 90% of new cases of the disease. More than 70% of kidney cancers are clear-cell tumors—named for the clearness (or paleness) of the cells when viewed under a microscope. [ Read More ]

Select Ongoing Trials Currently Enrolling Patients with Renal-Cell Carcinoma

February 2017, Vol 7, No 2 - Clinical Trials Tracker

The following studies represent a selection of key clinical trials that are currently recruiting patients with renal-cell carcinoma (RCC) for inclusion in investigations of new therapies or new combinations of available ther­apies for patients with kidney cancer. Each trial description includes the NLM Identifier to be used as a reference with ClinicalTrials.gov. The information below can help oncology practice managers and providers direct their eligible patients to one of these clinical trials. [ Read More ]